Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Not yet recruiting	Phase 2	2026-07-15		NCT07450183

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Henry Ford Health System	77
Regeneron Pharmaceuticals	238

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Henry Ford Health	Detroit	United States	75

Clinical trials